Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Jumping Again Today

By Keith Speights - Apr 14, 2021 at 11:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to still think that bad news for Johnson & Johnson could be good news for Novavax.

What happened

Shares of Novavax (NVAX 12.49%) were jumping 5.8% at 11:46 a.m. EDT on Wednesday. This marked the second consecutive day of solid gains for the biotech for the same reason: anticipation that problems related to Johnson & Johnson's (JNJ -0.77%) COVID-19 vaccine could bode well for Novavax's prospects. Novavax also announced some management changes after the market closed on Tuesday.

So what

Novavax has already committed to supplying 100 million doses of COVID-19 vaccine NVX-CoV2373 to the U.S. The biotech also has supply deals in place with other countries for around 200 million doses. It's possible that Novavax could receive more orders if governments are concerned about the safety of J&J's vaccine.

COVID-19 vaccine vial on its side next to a syringe and a vial standing up with a dollar sign in it

Image source: Getty Images.

Whether that happens, though, remains to be seen. The U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) called for a pause on the use of J&J's COVID-19 vaccine due to reports of blood clotting problems in some who received it. However, these cases were very rare (fewer than 1 in 1 million). The pause is likely to be only temporary.

The management changes announced by Novavax probably didn't affect the biotech stock very much, if at all. Novavax reported that it had promoted Gale Smith to senior vice president, discovery and pre-clinical research and chief scientist. It named Troy Morgan senior vice president and chief compliance officer. The company also said that Greg Covino will step down as CFO for personal reasons but will serve as an executive advisor.

Now what

The main thing to look for with Novavax over the near term is the company's progress toward securing Emergency Use Authorization for NVX-CoV2373. Novavax has already reported positive results from a late-stage study of the vaccine conducted in the U.K. and should soon wrap up a phase 3 study in the U.S. and Mexico.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$64.29 (12.49%) $7.14
Johnson & Johnson Stock Quote
Johnson & Johnson
$178.14 (-0.77%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.